Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Vaccine against mumps containing a JERYL-LYNN virus strain

A technology for mumps virus strains and vaccines, applied in measles-mumps-rubella combined vaccines, antisense single-stranded RNA viruses, positive-sense single-stranded RNA viruses, etc., can solve problems such as inability to guarantee balance and difficulty in estimating proportions

Inactive Publication Date: 2011-01-19
GLAXOSMITHKLINE BIOLOGICALS SA
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, as the Jeryl-Lynn strain is further passaged, there is no guarantee that this balance between the two variants will be maintained
It is also difficult to estimate the proportion of these two variants in any batch of vaccines

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Vaccine against mumps containing a JERYL-LYNN virus strain
  • Vaccine against mumps containing a JERYL-LYNN virus strain
  • Vaccine against mumps containing a JERYL-LYNN virus strain

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0037] 1) Preliminary sequencing of the SH gene

[0038] at 25cm 2 On the overgrown monolayer Vero cells in the culture flask, use dMEM Biorich medium (50 / 50 V / V) plus 0.5% fetal bovine serum, inoculate about 3.0log TCID 50 MumpsVax virus was commercially available for passaging. Incubate at 34°C for 7 days, then harvest infected cells, extract RNA by the method of Ferré and Garduno (Nucleic Acids Research 1989, 17; 2141), place in 100mcl water, and treat with diethylpyrocarbonate at 100°C 5 minutes. Take 5 mcl of such extracts and add the following reagents for reverse transcription: 40 units of RNAsin (Boehringer Mannheim, Germany), 4 mcl of 5X concentrated reverse transcriptase buffer (Bethesda Besearch Labs), 2 mcl of a mixture of four deoxynucleoside triphosphates The concentration was 10 mM, 10 pmole NH2 oligonucleotide primer, 1 mcl Moloney murine leukemia virus (MMLV) reverse transcriptase (Bethesda Research Labs, 200 units per mcl), and water was added to make th...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

A new mumps vaccine is presented, comprising a homogeneous pure isolate derived from the Jeryl-Lynn strain of mumps virus. In a preferred embodiment of the invention the vaccine produces higher seroconversion and antibody titres than known commercial vaccines.

Description

[0001] related application [0002] This application is a divisional application of Chinese application 200410003915.4. The filing date of the parent application is November 15, 1994. This divisional application adopts the same invention title as the parent application. technical field [0003] The present invention relates to a mumps vaccine comprising a homogeneous purified isolate derived from the Jeryl-Lynn strain of mumps virus. Background technique [0004] Mumps is basically a disease of children, usually with mild clinical symptoms. However, the clinical consequences of mumps infection are severe in some cases. For example, mumps is the most common cause of meningoencephalitis in children under 15 years of age and a cause of permanent sensorineural deafness in children in the United Kingdom. Although 30-40% of natural mumps infections are asymptomatic, the salivary glands are involved and, in the adult population, mumps causes first trimester abortion in addition t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12N7/04A61K39/165A61K39/295A61K39/25A61K39/20A61P31/14A61P31/22C12R1/93C12N15/09A61P31/04A61P31/12A61P31/20C07K14/12C12N7/00C12N7/01
CPCC12N2760/18722A61K2039/5254A61K39/165C12N2760/18734C12N7/00C07K14/005C12N2760/18762C12N2760/18721A61K2039/70C12N2760/18434C12N2770/36234A61K39/0015A61K39/12A61P31/04A61P31/12A61P31/14A61P31/20A61P31/22Y02A50/30
Inventor 奈杰尔·M·哈福德布里格特·D·A·科劳让·迪德莱兹
Owner GLAXOSMITHKLINE BIOLOGICALS SA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com